Compliance
Is Compounded Semaglutide Legal for Medspas? FDA Status & Compliance Risk
Compounded semaglutide exists in a gray zone—here's what medspa owners need to know about FDA enforcement, shortages, and liability.
Photo: fahri tokcan / Pexels
AI Inside MedSpa Intelligence · Jun 26, 2026
Compounded semaglutide is not explicitly approved by the FDA, and medspas offering it face significant regulatory and liability risk. While the FDA has not issued a blanket ban on compounding semaglutide, the agency has taken enforcement action against compounders and warned that compounded versions lack FDA oversight for safety, potency, and purity.
The Shortage & Compounding Gray Zone
When Ozempic and Wegovy faced supply shortages in 2022–2023, compounding pharmacies began preparing semaglutide under 503A (traditional pharmacy) and 503B (outsourcing facility) regulations. The FDA's position: compounding is permitted only when an FDA-approved drug is unavailable. As supply has normalized, that justification has weakened.
FDA Enforcement & Warnings
The FDA has issued warning letters to compounders and sent guidance to state boards emphasizing that:
- Compounded semaglutide is not bioequivalent to brand-name products
- Compounders must verify the active pharmaceutical ingredient (API) source and purity
- Medspas and clinics dispensing or administering compounded semaglutide may be liable for adverse events
- The agency does not review or approve compounded formulations before they reach patients
503A vs. 503B: What's the Difference?
- 503A pharmacies compound under state pharmacy board oversight; liability typically falls on the pharmacy and prescriber
- 503B outsourcing facilities operate under federal oversight but still face FDA scrutiny regarding ingredient sourcing and quality
Compounded semaglutide is not FDA-approved, and medspas offering it face regulatory action, liability claims, and state board discipline.
Neither pathway provides FDA pre-approval or guarantees safety.
Risk for Medspa Owners
Offering compounded semaglutide exposes your practice to:
- Regulatory action if the FDA determines compounding is no longer justified by shortage
- Liability claims if a patient experiences adverse effects and argues the product was substandard
- State board discipline if your state's pharmacy or medical board deems it outside scope of practice
- Reputational damage if compounded products are later recalled or investigated
What Owners Should Do
Verify current FDA and state guidance before offering any compounded GLP-1 agonist. Consider whether brand-name semaglutide (Ozempic, Wegovy) or other FDA-approved alternatives are available. If you do work with a compounder, ensure they are 503B-registered, provide certificates of analysis, and carry appropriate liability insurance.
The safest path: stick to FDA-approved injectables and document your rationale for any compounded product in patient records.
Frequently asked questions
Is compounded semaglutide legal for medspas to offer?
Compounded semaglutide is not explicitly FDA-approved, and medspas offering it face significant regulatory and liability risk. The FDA permits compounding only when an FDA-approved drug is unavailable, but as supply has normalized since 2022–2023, that justification has weakened. Medspas should verify current FDA and state guidance before offering it.
What's the difference between 503A and 503B compounding pharmacies?
503A pharmacies compound under state pharmacy board oversight, with liability typically falling on the pharmacy and prescriber. 503B outsourcing facilities operate under federal oversight but still face FDA scrutiny regarding ingredient sourcing and quality. Neither pathway provides FDA pre-approval or guarantees safety.
What liability do medspas face if they dispense compounded semaglutide?
Medspas may be held liable for adverse events if a patient argues the compounded product was substandard, and face potential regulatory action, state board discipline, and reputational damage. The FDA does not review or approve compounded formulations before they reach patients, leaving clinics exposed to enforcement action if compounding is deemed no longer justified.
Has the FDA taken action against compounders selling semaglutide?
Yes, the FDA has issued warning letters to compounders and sent guidance to state boards emphasizing that compounded semaglutide is not bioequivalent to brand-name products and lacks FDA oversight for safety, potency, and purity. The agency has warned that compounders must verify active pharmaceutical ingredient sourcing and purity.
What should medspas do if they want to offer semaglutide?
The safest approach is to stick to FDA-approved injectables like Ozempic and Wegovy. If you do work with a compounder, ensure they are 503B-registered, provide certificates of analysis, carry appropriate liability insurance, and document your rationale for using compounded products in patient records.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
